ELMSFORD, N.Y. — BioScrip on Wednesday posted $155.9 million in second-quarter revenue, up 18.5% compared with the prior year.
"The second-quarter results demonstrate our progress in executing on our strategic plan," BioScrip president and CEO Rick Smith said. "We were able to close on the divestiture of the noncore pharmacy services assets and redeploy a portion of the proceeds towards the acquisition of InfuScience, while delivering sequential improvement on our adjusted EBITDA."
